The disconnect between the primary policy assumption underpinning the HTA Review, which is that products must be found safe and effective to be funded, demonstrates the extent of this MSAC outcome as a dangerous outlier. …
The danger of this outlier is reflected in the disconnect with another policy process
October 18, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Noxopharm moves lupus skin therapy toward next human trial
September 14, 2026 - - Australian Biotech -
Entropy's psychedelic infusion keeps binge eating disorder at bay three months after treatment ends
September 14, 2026 - - Latest News -
Diabetes and cancer blood tests reach WA and NT patients under new Healius deal
September 14, 2026 - - Australian Biotech -
FDA clears Telix's Pixclara as the world's first approved brain cancer imaging drug
September 14, 2026 - - Australian Biotech -
Canberra details tax changes with limited concessions for some innovators
September 14, 2026 - - Latest News -
Scandal-hit KPMG still holds $37 million in health department work
September 14, 2026 - - Latest News -
Todd Stephenson confirmed on ACT list for New Zealand election
September 14, 2026 - - Latest News